BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough

Stock Information for BELLUS Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BELLUS Health Inc.

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
BELLUS Health to Present at the American Thoracic Society 2021 International Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.